emtricitabine (Emtriva, FTC)
Jump to navigation
Jump to search
Introduction
Tradename: Emtriva
Indications
Dosage
Dosage adjustment in renal failure
- dosage reduction if creatinine clearance < 50 mL/min
Pharmacokinetics
- hepatic oxidation & glucuronidation
- cyt P450 system not involved
- clearance 86% renal, 14% fecal
- 2/1life 10 hours
Adverse effects
Drug interactions
unlikely
Mechanism of action
- inhibits viral reverse transcriptase
- has activity against hepatitis B virus[3]
More general terms
Component of
- cobicistat/darunavir/emtricitabine/tenofovir
- bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy, Symtuza)
- cobicistat/elvitegravir/emtricitabine/tenofovir (Quad, Stribild, Genvoya)
- emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF, TAF/FTC/RPV, Complera, Odefsey)
- emtricitabine/tenofovir (Truvada, TDF/FTC, Descovy)
- efavirenz/emtricitabine/tenofovir (Atripla)
References
- ↑ Prescriber's Letter 10(8):45 2003
- ↑ Department of Veterans Affairs, VA National Formulary
- ↑ Jump up to: 3.0 3.1 3.2 Lim SG et al, A double-blind placebo-controlled study of emtricitrabine in chronic hepatitis B Arch Intern Med 2006; 166:49 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16401810